[Plasma lipoprotein(a) levels in patients with hyperthyroidism].
Recently lipoprotein(a) [Lp(a)], which is an atherogenic giant lipoprotein, has been proved to be a major independent risk factor in cardiovascular and cerebrovascular diseases. Therefore, it is important to study the clinical role of the reduction of plasma Lp(a) in atherosclerosis prevention. In this study we examined the role of plasma Lp(a) levels in patients with hyperthyroidism (HT) in which is commonly observed low levels of total and LDL cholesterol. Plasma Lp(a) levels in 6 men and 17 women aged 17 to 67 (mean 36) years with HT ranged from 0.1 to 17.8 (mean +/- SE; 5.3 +/- 1.0) mg/dl. Those of 36 healthy men and 69 healthy women aged 15 to 73 (mean 41) years ranged from 0.2 to 30.2 (10.7 +/- 0.7)mg/dl, and those of 9 men and 26 women aged 17 to 68 (mean 41) years with HT during treatment more than 6 months ranged from 3.6 to 45.7 (11.1 +/- 1.6)mg/dl. The mean values for Lp(a) in HT were significantly lower than those of the healthy subjects (p < 0.001) or HT during treatment (p < 0.025). Those low levels of Lp(a) in patients with HT were normalized after the appropriate treatment (8.9 +/- 1.4 mg/dl, p < 0.05). A significant correlation was noted between the changes of plasma Lp(a) and LDL cholesterol levels in HT before and after treatment (r = 0.62, p < 0.05). In conclusion, we found that plasma Lp(a) was lowered in patients with HT, and those lowered levels were normalized after treatment.(ABSTRACT TRUNCATED AT 250 WORDS)
Matsubara
M
M
Otaru City General Hospital.
Atsumi
T
T
Namioka
K
K
D000293:Adolescent; D000328:Adult; D000368:Aged; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D006980:Hyperthyroidism / Q000097:blood* / Q000188:drug therapy; D017270:Lipoprotein(a) / Q000097:blood*; D008297:Male; D008875:Middle Aged; D012307:Risk Factors; D013963:Thyroid Hormones / Q000627:therapeutic use
D017270:Lipoprotein(a); D013963:Thyroid Hormones